Vimarsana
Biggest News Aggregation in the World

Page 2 - Unique Case News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Unique Case. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Unique Case Today - Breaking & Trending Today

New Recovery from HIV: The Geneva Patient's Case Breaks Ground in AIDS Research - Vimarsana News

New Recovery from HIV: The Geneva Patient's Case Breaks Ground in AIDS Research

Geneva Patient's Recovery from AIDS A Man Known as the "Geneva Patient" Recovers from AIDS Introduction A man known as the "Geneva Patient" entered a long

BYJU's 3 Board Members as well as Auditor Deloitte, Resigned, Say Reports - Vimarsana News

BYJU's 3 Board Members as well as Auditor Deloitte, Resigned, Say Reports

Three members on the board of education technology (ed-tech) company BYJU's have reportedly resigned over differences with the ed-tech founder Byju Ravindran. Meanwhile, Deloitte Haskins & Sells LLP, the statutory auditor of the ed-tech, whose financial statements for FY21-22 are long delayed, have also resigned, say reports. Meanwhile, BYJU's has appointed BDO (MSKA & Associates) as its statutory auditors.

BYJU's 3 Board Members as well Auditor Deloitte, Resigned, Say Reports - Vimarsana News

BYJU's 3 Board Members as well Auditor Deloitte, Resigned, Say Reports

Three members on the board of education technology (ed-tech) company BYJU's have reportedly resigned over differences with the ed-tech founder Byju Ravindran. Meanwhile, Deloitte Haskins & Sells LLP, the statutory auditor of the ed-tech, whose financial statements for FY21-22 are long delayed, have also resigned, say reports. Meanwhile, BYJU's has appointed BDO (MSKA & Associates) as its statutory auditors.

Personalized mRNA Vaccines Could Significantly Reduce Risk of Melanoma Relapse - Vimarsana News

Personalized mRNA Vaccines Could Significantly Reduce Risk of Melanoma Relapse

Moderna and Merck recently finished a phase 2 trial for personalized mRNA vaccines for melanoma patients. The vaccine uses genetic material from a person’s tumor to develop a vaccine that teaches a person’s immune system to identify cells that match that tumor, attacking those cells before they have a chance to grow.

Source: health.com
As You Move to the Cloud, Don't Leave Your People on the Ground (Part 1 of 2) | Transforming Data with Intelligence - Vimarsana News

As You Move to the Cloud, Don't Leave Your People on the Ground (Part 1 of 2) | Transforming Data with Intelligence

With every technology change, there will be a variety of responses from the people in your organization. Understanding the personality and response types will help you retain and protect your staff.

Source: tdwi.org